Background: Large cell neuroendocrine carcinoma (LCNEC) of the prostate is an extremely rare entity, and the clinicopathological course, potential effective treatment, and prognosis are yet to be elucidated. Materials and Methods: A systematic search in Pubmed, Embase, and Ovid from inception to January 2019 was conducted. We reviewed each individual case of prostatic LCNEC and summarized specific features and outcomes for this rare pathologic entity. Results: Thirteen studies with a total of 20 patients (mean age: 70.3, range 43–87) were included in our review. Seventeen patients harbored primary LCNEC of the prostate, of which 9 patients were diagnosed with de novo carcinoma, and 8 patients were with a history of prostatic adenocarcinoma treated with hormonal therapy (mean duration: 2.9 years, range 2–5). The other 3 patients were diagnosed with metastatic LCNEC originating from lung (2 cases) and bladder (1 case). All patients met the diagnostic criteria of the typical morphological features as well as immunohistochemical staining results. Nearly all primary de novo LCNEC of the prostate were at a late stage at initial diagnosis. The pattern of distant metastasis resembled that of prostatic adenocarcinoma with the most common sites as bone spread (8/16, 50%). Most patients received systematic chemotherapy after diagnosis; however, the prognosis remained poor and patients deteriorated rapidly but with exception. Three reported cases in the context of de novo LCNEC admixed with prostatic adenocarcinoma kept sustained response to androgen deprivation therapy (ADT) and achieved obviously better survival outcomes compared with other patients. Conclusions: LCNEC of the prostate is a rare entity that mostly occurs after long-standing hormonal therapy of prostatic adenocarcinoma. The prognosis was universally poor irrespective of the systematic chemotherapy. However, patients of de novo tumor mixed with prostatic adenocarcinoma may respond to ADT and harbor a better outcome than those of pure de novo or post-ADT LCNEC of the prostate.

Keywords:
Prostate cancer, Large cell, Neuroendocrine carcinoma
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7–30.
2.
Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah SR, Moschini M, et al. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. Clin Genitourin Cancer. 2017 Oct;15(5):e793–800.
3.
Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol. 2014 Oct;32(30):3383–90.
4.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul;70(1):106–19.
5.
Priemer DS, Montironi R, Wang L, Williamson SR, Lopez-Beltran A, Cheng L. Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. Endocr Pathol. 2016 Jun;27(2):123–35.
6.
Tzou KY, Cheng WH, Lee WH, Ho CH. Primary large cell neuroendocrine carcinoma of the prostate in a hormone naive patient: A case report from Taiwan. J Cancer Res Ther. 2018 Sep;14(10 Supplement):S785–8.
7.
Miyakawa J, Suzuki M, Endo K, Nose Y, Sato T, Kishida Y, et al. A rare case of de novo large cell neuroendocrine carcinoma of the prostate with long-term survival after cystoprostatectomy and androgen deprivation. Urol Case Rep. 2018 Sep;21:95–7.
8.
Papagoras C, Arelaki S, Botis I, Chrysafis I, Giannopoulos S, Skendros P. Co-occurrence of Dermatomyositis and Polycythemia Unveiling Rare de Novo Neuroendocrine Prostate Tumor. Front Oncol. 2018 Nov;8:534.
9.
Azad AA, Jones EC, Chi KN. Metastatic large-cell neuroendocrine prostate carcinoma: successful treatment with androgen deprivation therapy. Clin Genitourin Cancer. 2014 Aug;12(4):e151–3.
10.
Acosta-Gonzalez G, Qin J, Wieczorek R, Melamed J, Deng FM, Zhou M, et al. De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. Am J Clin Exp Urol. 2014 Dec;2(4):337–42.
11.
Okoye E, Choi EK, Divatia M, Miles BJ, Ayala AG, Ro JY. De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature. Int J Clin Exp Pathol. 2014 Dec;7(12):9061–6.
12.
Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006 Jun;30(6):684–93.
13.
Wynn SS, Nagabundi S, Koo J, Chin NW. Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch Pathol Lab Med. 2000 Jul;124(7):1074–6.
14.
Patel R, Faiena I, Geltzeiler J. Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy. Can J Urol. 2015 Apr;22(2):7752–4.
15.
Moratalla Charcos LM, Pastor Navarro T, Cortes Vizcaino V, Osca Garcia JM, Gil Salom M. Large-cell neuroendocrine carcinoma of prostate. Case report. Arch Esp Urol. 2013 May;66(4):368–71.
16.
Lin D, Tan AJ, De Sousa AF, Singh-Rai R. A rare case of large cell neuroendocrine carcinoma. BMJ Case Rep. 2014 Oct 19;2014.
17.
Shimizu K, Goto T, Maeshima A, Oyamada Y, Kato R. Prostatic metastasis of pulmonary large cell neuroendocrine carcinoma. J Cancer. 2012;3:96–9.
18.
Yoo JH, Lee JH, Kim EK, Hong YK, Lee Y, Jeong HC. Prostatic metastasis of large cell neuroendocrine carcinoma of the lung. Respirology. 2009 Jul;14(5):772–5.
19.
Liu Y, Zhao S, Wang J, Zhu Z, Luo L, Li E, et al. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. Urol Int. 2018 Dec 5:1–12.
20.
Epstein JI, Amin MB, Beltran H, Lotan TL, Mosquera JM, Reuter VE, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014 Jun;38(6):756–67.
21.
Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012 Jan;60(1):59–74.
22.
Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000 May;36(5):415–20.
23.
Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 Jul;16(7):807–21.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.